Latest Industry Insights

Cutting-edge mass spectrometry proteomics technologies are accelerating the discovery and validation of novel targets in cancer, opening up new avenues for next-generation cancer therapeutics.

Hear how the capabilities of mass spectrometry (MS)-based proteomics are proving themselves in drug development and discovery and what this means for those working in oncology.

Revvity announced its newly established Scientific Centre of Excellence in Cambridge, where scientists can outsource their research needs to Revvity experts. Technology Networks visited the site to learn more about how Revvity is supporting its customers in their drug discovery efforts.

This article examines the impact of the democratization of computational design and discusses how synthetic biology companies must shift focus if they are to remain competitive.

New applications for RNA therapeutics are continuously emerging. In this burgeoning space, nucleic acid quantification can help this dynamic therapeutic modality reach its full potential.

Trial sponsors are faced with vast amounts of diverse data and corresponding endpoints spanning all trial sites linked to their study design. This article explores how interactive response technology can help sponsors overcome these challenges.

This article discusses why the proactive detection and monitoring of viral threats through genomics studies is vital in preventing future pandemics and empowering healthcare providers in the face of increasing globalization.

At AACR 2023, Technology Networks spoke with Dr. Mark Garner, global cancer segment market manager at Agilent Technologies, to learn how the new SureSelect Cancer CGP assay is empowering the cancer research field.

At ASMS, Technology Networks spoke with Ken Suzuki and Jennifer Gushue to learn more about how Agilent is addressing customer needs with novel “intelligence” features and the company’s efforts to ensure the sustainability and longevity of its products.

Researchers have made significant strides toward developing improved battery chemistries, but scaling up production is challenging. To find out more, we spoke to Zhao Liu, senior market development manager at Thermo Fisher Scientific.